EAL® WAS GRANTED BREAKTHROUGH THERAPY BY THE CENTER FOR DRUG EVALUATION

The first investigator meeting of Phase I Denocabtagene Ciloleucel Injection (Originally known as RC19D2) successfully held by Immunotech Biopharm Ltd

OBTAINED PHASE I CLINICAL TRIAL APPROVAL FOR DENOCABTAGENE CILOLEUCEL INJECTION (ORIGINALLY KNOWN AS RC19D2, CAR-T-D2, CAR-T-19-DNR)

IMMUNOTECH BIOPHARM LTD DEBUTED AT THE ZHONGGUANCUN FORUM WITH EAL, AND CEO DR. WANG YU GAVE A WONDERFUL PRESENTATION AT THE 2023 ZHONGGUANCUN INTERNATIONAL TECHNOLOGY TRADING CONFERENCE

TALKING ABOUT THE FRONTIERS OF CELL THERAPY INDUSTRY TOGETHER, STANDARDS EMPOWER SUSTAINABLE DEVELOPMENT OF ENTERPRISES

DR. WANG YU, CEO OF YONGTAI BIO-B (06978. HK), ATTENDED THE BOAO FORUM FOR ASIA HEALTH INDUSTRY INTERNATIONAL FORUM - CELL GENE THERAPY AND INDUSTRIALIZATION DEVELOPMENT SUB FORUM AND DELIVERED A KEYNOTE SPEECH

THE COMPANY HELD A GRAND SPEECH ON THE SPIRIT OF THE 20TH CPC NATIONAL CONGRESS

THE COMPANY'S 2022 ESG REPORT STAKEHOLDER SURVEY

SPRING FESTIVAL GREETINGS AND BEST WISHES TO ALL YONGTAI STAFF

THE COMPANY HELD THE 2022 YEAR-END REVIEW AND COMMENDATION AND 2023 ANNUAL PLANNING MEETING